
Opinion|Videos|July 4, 2024
Topical Ruxolitinib in Vitiligo: Efficacy, Regional Approvals, and Treatment Strategies in African American Patients
Author(s)Latanya Benjamin, MD, FAAD, FAAP
Dr. Latanya Benjamin, MD, FAAD, FAAP, discusses the role of topical ruxolitinib cream in managing vitiligo and its effectiveness in a 25-year-old female patient.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5



















